UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045253
Receipt number R000051693
Scientific Title Effect of iron-containing food intake on metabolism for iron
Date of disclosure of the study information 2021/08/24
Last modified on 2022/02/22 09:07:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effect of iron-containing food intake on metabolism for iron

Acronym

Effect of iron-containing food intake on metabolism for iron

Scientific Title

Effect of iron-containing food intake on metabolism for iron

Scientific Title:Acronym

Effect of iron-containing food intake on metabolism for iron

Region

Japan


Condition

Condition

Healthy women

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Purpose of this clinical test are the effect of the test food, iron derived from beans, on the recovery of iron levels after menstruation, and to assess the usefulness and safety of iron derived from beans.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Change in hemoglobin before and after intervention

Key secondary outcomes

Ferritin, red blood cells, serum iron, serum zinc, serum copper, hematocrit, TIBC, MCH, MCHC, anemia symptoms questionnaire, OSA sleep questionnaire, anti-fatigue questionnaire


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Food

Interventions/Control_1

Intake of foods containing pea-derived ferritin iron

Interventions/Control_2

Intake of Placebo

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

60 years-old >=

Gender

Female

Key inclusion criteria

(1) Women who experience iron deficiency on a daily basis (anemia symptoms)
(2) Premenopausal women
(3) Women with a BMI of less than 30 kg/m2
(4)Those whose menstruation is in a designated cycle (within 1 week of the end of menstruation on July 28 and 29: follicular phase, end of menstruation on August 3 and 4 or within 3 days of the end of menstruation)
(5)Those whose menstrual cycle is relatively stable
(6)Those who can voluntarily consent to participate in the study in writing
(7) Patients who have had a hemoglobin level of less than 13 g/dL (preferably less than 12 g/dL) in a previous blood test

Key exclusion criteria

(1) Those who are allergic to beans (soybeans, peas, and other legumes in general)
(2) Those who are currently on medication for iron deficiency anemia.
(3) Those who are currently receiving medication for any disease.
(4) Those who are taking the food (soy milk) or health food containing the ingredients of this test food
(5) Those with irregular menstrual cycles
(6) Persons with serious diseases of glucose metabolism, lipid metabolism, liver function, kidney function, heart, circulatory system, respiratory system, endocrine system, immune system, nervous system, or mental disorders. (6) Those who have a history of serious diseases or mental disorders, and those who have a history of such diseases.
(7) Those who have abnormal clinical laboratory values and are judged to have a problem with participation in the study.
(8) Those who have a disease under treatment or a history of serious disease requiring medication.
(9) Those who may develop allergies related to the study.
(10)Those who are judged to be unsuitable as subjects based on the results of the answers to the lifestyle questionnaire.
(11)Those who are participating in other clinical research at the time of the start of this study.
(12) Those who are pregnant or plan to become pregnant or breastfeed during the study period
(13) Patients with uterine fibroids or endometriosis
(14)Those who are judged by the principal investigator to be unsuitable for participation in the study.

Target sample size

42


Research contact person

Name of lead principal investigator

1st name Yujji
Middle name
Last name Kuriyama

Organization

Juntendo University School of Medicine

Division name

Department of General Medicine

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421 Japan

TEL

03-3813-311

Email

kuri@a2-pro.com


Public contact

Name of contact person

1st name Yoshihiro
Middle name
Last name Otake

Organization

feileB Co.Ltd

Division name

Clinical Trial Session

Zip code

160-0015

Address

7th Floor Gran-First Shinjyuku-Gyoen Bldg, 22-1 Daikyo-cho, Shinjyuku-ku, Tokyo 160-0015, Japan

TEL

03-6416-4228

Homepage URL


Email

otake@feileb.jp


Sponsor or person

Institute

Anti-Aging Pro Corporation

Institute

Department

Personal name



Funding Source

Organization

Anti-Aging Pro Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Tsukiji Futaba Clinic institutional review board

Address

Hosokawa-Tsukiji Build. 6F, Tsukiji 1-9-9, Cyuou-ku, Tokyo

Tel

03-6226-5812

Email

tohru@hikobae.net


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 08 Month 24 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 07 Month 19 Day

Date of IRB

2021 Year 07 Month 20 Day

Anticipated trial start date

2021 Year 08 Month 25 Day

Last follow-up date

2021 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 08 Month 24 Day

Last modified on

2022 Year 02 Month 22 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051693


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name